Spots Global Cancer Trial Database for Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases
Official Title: Phase 1 Open Label, Dose Escalating, Multiple Dose Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, and Pharmacokinetics of MPC-6827 Administered IV Weekly X 3, Repeated Every 28 Days, in Subjects With Refractory Brain Metastases
Study ID: NCT00393965
Conditions
Interventions
Study Description
Brief Summary: Phase 1, Multiple dose Study of MPC-6827 in Subjects with Refractory Brain Metastases.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
MD Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: Margaret Yu, MD
Affiliation: Myrexis Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
